Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin : one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol. 1999, 117, 1329-1345
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin : two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001, 119, 198-207
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin : additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002, 120, 1443-1454
Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration : two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001, 131, 541-560
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for horoidal neovascularization secondary to age-related macular degeneration : TAP and VIP report no. 1. Am J Ophthalmol. 2003, 136, 407-418